Diagnosis and Management of Dermatologic Adverse Events from Systemic Melanoma Therapies

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Advanced melanoma management has been revolutionized by protein kinase inhibitors and immunotherapy.
• These treatments, while effective, can cause significant drug-related toxicities affecting multiple organ systems.
• Dermatologic adverse events are a notable concern, impacting patient quality of life and treatment outcomes.

Purpose of the Study:

• To review dermatologic adverse events associated with targeted melanoma therapies (BRAF and MEK inhibitors) and other treatments.
• To focus on the diagnosis and management of these skin toxicities.
• To briefly discuss injectable talimogene laherparepvec and recent immunotherapy advancements.

Main Methods:

• Literature review of dermatologic adverse events from targeted and other melanoma treatments.
• Focus on diagnostic criteria and established management strategies.
• Inclusion of recent data on talimogene laherparepvec and immunotherapy breakthroughs.

Main Results:

• Targeted therapies (BRAF/MEK inhibitors) and other melanoma treatments frequently cause diverse dermatologic adverse events.
• These skin toxicities can significantly affect patient quality of life.
• Dermatologic adverse events are often correlated with treatment response and overall survival.

Conclusions:

• Clinicians must be aware of the varied presentations of melanoma treatment-related dermatologic toxicities.
• Prompt and accurate diagnosis and management of skin adverse events are essential.
• Effective management of these toxicities is critical for maintaining patient quality of life and potentially improving survival outcomes.